Retinoids as differentiating agents in oncology: a network of interactions with intracellular pathways as the basis for rational therapeutic combinations.
about
A forward chemical screen in zebrafish identifies a retinoic acid derivative with receptor specificityThe proteasome inhibitor bortezomib enhances ATRA-induced differentiation of neuroblastoma cells via the JNK mitogen-activated protein kinase pathwayω-3 free fatty acids and all-trans retinoic acid synergistically induce growth inhibition of three subtypes of breast cancer cell linesTherapeutic potential of the inhibition of the retinoic acid hydroxylases CYP26A1 and CYP26B1 by xenobiotics.Induction of miR-21 by retinoic acid in estrogen receptor-positive breast carcinoma cells: biological correlates and molecular targets.Association of FABP5 expression with poor survival in triple-negative breast cancer: implication for retinoic acid therapySubstrate specificity and ligand interactions of CYP26A1, the human liver retinoic acid hydroxylase.CRABP1 is associated with a poor prognosis in breast cancer: adding to the complexity of breast cancer cell response to retinoic acid.Cellular and molecular determinants of all-trans retinoic acid sensitivity in breast cancer: Luminal phenotype and RARα expression.Non-DHFR-mediated effects of methotrexate in osteosarcoma cell lines: epigenetic alterations and enhanced cell differentiationOvercoming retinoic acid-resistance of mammary carcinomas by diverting retinoic acid from PPARbeta/delta to RAR.Carbonyl Reductase 3 (CBR3) Mediates 9-cis-Retinoic Acid-Induced Cytostatis and is a Potential Prognostic Marker for Oral Malignancy.Role of the molybdoflavoenzyme aldehyde oxidase homolog 2 in the biosynthesis of retinoic acid: generation and characterization of a knockout mouseTransglutaminase-2 Is Involved in All-Trans Retinoic Acid-Induced Invasion and Matrix Metalloproteinases Expression of SH-SY5Y Neuroblastoma Cells via NF-κB Pathway.Epigenetic silencing of CRABP2 and MX1 in head and neck tumors.RARα2 and PML-RAR similarities in the control of basal and retinoic acid induced myeloid maturation of acute myeloid leukemia cellsAssociation between cytoplasmic CRABP2, altered retinoic acid signaling, and poor prognosis in glioblastomaAntiproliferative and differentiating activities of a novel series of histone deacetylase inhibitors.Estrogen and retinoic acid antagonistically regulate several microRNA genes to control aerobic glycolysis in breast cancer cells.p38αMAPK interacts with and inhibits RARα: suppression of the kinase enhances the therapeutic activity of retinoids in acute myeloid leukemia cells.Synergistic antitumor activity of lapatinib and retinoids on a novel subtype of breast cancer with coamplification of ERBB2 and RARA.Enhancement of ATRA-induced differentiation of neuroblastoma cells with LOX/COX inhibitors: an expression profiling study.The ATRA-induced differentiation of medulloblastoma cells is enhanced with LOX/COX inhibitors: an analysis of gene expression.Flavonoid 4'-O-Methylkuwanon E from Morus alba Induces the Differentiation of THP-1 Human Leukemia CellsRetinoids and breast cancer: new clues to increase their activity and selectivity.Therapeutic cytodifferentiation in alveolar rhabdomyosarcoma without genetic change of the PAX3-FKHR chimeric fusion gene: a case study.[Expressions and significances of CRABPII and E-FABP in non-small cell lung cancer].
P2860
Q28473528-DD687CA6-C59F-41DB-B742-0161E77F3E5DQ28477838-360F15B5-5EAB-4928-A59C-E836A162AA2AQ33774367-FDBD739A-89F2-4FF0-BC30-275B606228B8Q34345596-616B11B2-E982-4DB2-8735-5C7AE5292E85Q34537141-4B98FE59-13FF-4193-9671-AA2A54A5570AQ34760876-90490BBC-3B15-4EEB-BD25-5198ADFF21AFQ35122815-3B6BC34E-BB9A-4B9E-9100-65496C09E238Q35817482-E9F8B07A-8BD4-4422-9703-1BA033BEB2F3Q35904255-C83B21D1-4CF6-464E-8F31-5A68E51B72F4Q36628909-753B9205-8625-43C8-A262-D97A22ADEB36Q36677182-F66EA8EF-6E46-4B56-AA62-B941A80D88E7Q36968288-70C620C4-72E5-4DA7-A951-99A3D5147541Q37033659-0A29966E-D284-45AE-9362-3787578EB724Q37224569-5A9345E6-6A84-44AF-866B-A43EB568AB6BQ38347884-55C80EA5-C8FF-48BC-8668-9AB8A59BE366Q38758034-122C88C6-CBD8-4023-8952-31209F4072EDQ38792793-C2D5EA72-D105-4848-A11F-89DA6D45B3F1Q39157795-DCAB83AA-3D9D-4D44-8137-8023B5B8E8DFQ39259747-4A704D18-B136-46E8-8795-33056A6D85A3Q39392644-3B60B1B5-5639-4D75-87BF-A665D4853384Q39447519-A5AA6917-8FEB-4ACA-B82D-1EF33AFD1E6DQ39705238-79393894-80E4-4A0D-A597-DF2AE8B96301Q40999604-C9DAA08E-4D2E-4CB8-AEF4-306573E9A0A3Q42096403-49317DC4-DE74-4BDE-B0F8-61DA627D5634Q42669872-A29E4D72-1CD7-4CB3-A361-EC3A7504DEDCQ45895047-46924111-E671-4BF7-B9C7-20C6427C9D8EQ55427757-4688ED7B-604B-47ED-A789-AE713866EDA4
P2860
Retinoids as differentiating agents in oncology: a network of interactions with intracellular pathways as the basis for rational therapeutic combinations.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Retinoids as differentiating a ...... onal therapeutic combinations.
@ast
Retinoids as differentiating a ...... onal therapeutic combinations.
@en
type
label
Retinoids as differentiating a ...... onal therapeutic combinations.
@ast
Retinoids as differentiating a ...... onal therapeutic combinations.
@en
prefLabel
Retinoids as differentiating a ...... onal therapeutic combinations.
@ast
Retinoids as differentiating a ...... onal therapeutic combinations.
@en
P2093
P1476
Retinoids as differentiating a ...... onal therapeutic combinations.
@en
P2093
Enrico Garattini
Maurizio Gianni
Mineko Terao
P304
P356
10.2174/138161207780618786
P577
2007-01-01T00:00:00Z